CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 23 of the 36 sources its claims cite were checked for support.

Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis

Open access

Abstract

The apolipoprotein E ( APOE ) - ε4 allele is the strongest genetic risk factor for late-onset, sporadic Alzheimer's disease, likely increasing risk by altering amyloid-β (Aβ) accumulation. We recently demonstrated that the low-density lipoprotein receptor (LDLR) is a major apoE receptor in the brain that strongly regulates amyloid plaque deposition. In the current study, we sought to understand the mechanism by which LDLR regulates Aβ accumulation by altering Aβ clearance from brain interstitial fluid. We hypothesized that increasing LDLR levels enhances blood–brain barrier-mediated Aβ clearance, thus leading to reduced Aβ accumulation. Using the brain Aβ efflux index method, we found that blood–brain barrier-mediated clearance of exogenously administered Aβ is enhanced with LDLR overexpression. We next developed a method to directly assess the elimination of centrally derived, endogenous Aβ into the plasma of mice using an anti-Aβ antibody that prevents degradation of plasma Aβ, allowing its rate of appearance from the brain to be measured. Using this plasma Aβ accumulation technique, we found that LDLR overexpression enhances brain-to-blood Aβ transport. Together, our results suggest a unique mechanism by which LDLR regulates brain-to-blood Aβ clearance, which may serve as a useful therapeutic avenue in targeting Aβ clearance from the brain.

Overview

CoChat Summary

TL;DR

LDLR overexpression in mouse models increases blood–brain barrier-mediated clearance of Aβ from brain interstitial fluid to blood, reducing Aβ accumulation. The effect appears indirect, involving reduced apoE and LRP1 at the BBB.

Key findings

  • In brain efflux index experiments, LDLR overexpression increased BBB-mediated Aβ clearance: BBB transport accounted for 66.9% of total Aβ clearance in TG vs. 36.3% in NTG, while brain retention was 27.8% vs. 58.6%; ISF bulk flow was similar (5.1% vs. 5.3%).
  • In 10-mo PDAPP/LDLR mice, hippocampus and cortex had 2.7-fold and 4.8-fold less Aβ burden than PDAPP littermates; fibrillar amyloid burden was also reduced, and apoE levels were decreased 2.9-fold and 2.5-fold.
  • Using anti-Aβ antibody HJ5.1 to stabilize plasma Aβ, the plasma appearance rate of CNS-derived human Aβ was faster in PD-TG than PD-NTG mice (92 ± 4.8 vs. 69 ± 6.9 pg·mL−1·min−1).
  • Blocking LRP1 with an anti-LRP1 antibody attenuated the BBB component of Aβ clearance in LDLR-TG mice, suggesting LRP1 partly mediates the effect.

Methods

  • Brain efflux index (BEI): 12 nM [125I]Aβ40 coinjected with [14C]inulin into brain ISF of 4–5 mo NTG and LDLR-TG mice; kinetic modeling estimated BBB transport, ISF bulk flow, and brain retention.
  • Cross-bred LDLR-TG with PDAPP (APP-V717F) mice; measured Aβ burden, fibrillar amyloid, apoE, and ISF Aβ in 3–4 or 10 mo mice; in vivo microdialysis assessed ISF Aβ.
  • Plasma accumulation: 250 μg HJ5.1 anti-Aβ antibody i.v., serial retro-orbital plasma samples 20–240 min, human Aβ quantified by immunoprecipitation/mass spectrometry; rates from linear regressions.

Limitations

  • Stated: the BEI method uses a kinetic model that cannot perfectly describe complex BBB physiology, and rapid peripheral distribution of Aβ makes following radiolabeled Aβ into blood difficult.
  • Stated: peripheral HJ5.1 did not alter brain ISF Aβ over 5 h, but longer-term effects of anti-Aβ antibodies on brain Aβ metabolism were not assessed; microdialysis may be insensitive to initial equilibrium changes.
  • Stated/evident: LDLR overexpression was in neurons and astrocytes, not BBB cells, so the proposed LRP1/apoE cross-talk is speculative; the study is in mouse models, and a role for LDLR in cell-type-specific Aβ degradation could not be ruled out.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1206446109

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 1 Not valid · 5 Not checked · 39 Own results and interpretations

32 more claims · 3 with their cited sources checked

Create a free account to see all 56 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 51 references

Cited by

See all 157

Metadata

Authors
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., & Holtzman, D. M.
Affiliations
  • Washington University in St. Louis (US)
  • University of Rochester Medicine (US)
  • Hope Center for Neurological Disorders (US)
  • C2N Diagnostics (United States) (US)
  • Eli Lilly (United States) (US)
  • Department of Physiology and Biophysics, Zilkha Neurogenetic Institute, University of Southern California Keck School of Medicine, Los Angeles, CA 90089
Venue
Proceedings of the National Academy of Sciences
Published
2012-08-27
Volume
109
Issue
38
Pages
15502-15507
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2017624892
Cited by
154
References
51
Citations by year
2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 16 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 3 · 2017: 10 · 2016: 11 · 2015: 15 · 2014: 29 · 2013: 14
FWCI
12.34
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5p30ns069329-02)
  • National Institute on Aging (R01AG023084, R01AG013956, R37AG023084, F31AG034004, R01AG035083, AG029481, AG034004, R01AG029481, P50AG005681, P01AG003991, R37AG013956, AG13956, K23AG030946, AG023084, P01AG026276, U24AG021886)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056341)
  • National Institute of Neurological Disorders and Stroke (P30-NS069329, NS034467, R37NS034467, P30NS057105, NS34467, R01NS034467)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
LDL receptor, amyloid-beta clearance, blood-brain barrier, Alzheimer's disease, APOE ε4, brain interstitial fluid, amyloid plaques, anti-amyloid antibodies, apoE receptors
MeSH terms
Alleles, Amyloidosis, Animals, Blood-Brain Barrier, Brain, Disease Models, Animal, Insulin, Kinetics, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Transgenic, Receptors, LDL, Amyloid beta-Peptides, Microdialysis, Transgenes, Mice, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. https://app.cochat.ai/papers/10.1073/pnas.1206446109
The paper
Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., & Holtzman, D. M. (2012). Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1206446109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.